Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma

Haematologica. 2023 Dec 1;108(12):3502-3505. doi: 10.3324/haematol.2023.283452.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Cyclophosphamide / therapeutic use
  • Dexamethasone / therapeutic use
  • Humans
  • Multiple Myeloma* / drug therapy
  • Stem Cells

Substances

  • daratumumab
  • Cyclophosphamide
  • Antibodies, Monoclonal
  • Dexamethasone